top of page

The Team

Cat _.jpeg

Catriona Jamieson

Founder
Chief Executive Officer
Dr. Catriona Jamieson is a co-founder and CEO of Aspera Biomedicines. She was a co-founder of Impact Biomedicines. Dr. Jamieson is a specialist in leukemia and myeloproliferative neoplasms. She is the Director of the Sanford Stem Cell Clinical Center, and Professor of Medicine. She has a PhD in Microbiology/Immunology and an MD from the University of British Columbia. She trained in hematology, bone marrow transplantation and stem cell biology followed by being an attending hematologist at Stanford University prior to being recruited to UCSD.
 
Sheldon Morris 1 (2).jpg

Sheldon Morris

Co-Founder
Chief Medical Officer
Dr. Sheldon Morris is a co-founder and the CMO of Aspera Biomedicines. He is currently a Professor of Infectious Diseases and Public Health at the UCSD School of Medicine. He has an MD from the University of British Columbia and an MPH for Harvard School of Public Health. He has board certifications in Preventive Medicine and Family Medicine. His expertise is in clinical trial design, management and conduct.
 
Mike_2019.jpg

Michael Burkart

Co-Founder
Director of R&D
Dr. Michael Burkart is a co-founder of Aspera Biomedicines and Director of Research & Development. He is currently a Professor and Chair of Chemistry and Biochemistry at University of California, San Diego. Mike grew up in Texas and received a B.A. in Chemistry from Rice University. After a PhD from the Scripps Research Institute and postdoctoral fellowship at Harvard Medical School, he initiated his own research group at UC San Diego in 2002, which focuses on natural products and drug discovery, including anticancer drug discovery through spliceosome modulation.
IMG_9881_edited_edited_edited_edited.jpg

John Mack

Chief Financial Officer
John Mack, CPA, is the CFO of Aspera Biomedicines. He has 20+ years of experience as a financial controller at both small and large businesses. His expertise is in the management of cash flow, compliance with financial regulations, and financial analysis. He has a BS in Accounting and has directed accounting activities at the private, state, and federal level.
 
me_edited.jpg

Karla Mack

Chief Strategy Officer
Karla Mack is the CSO for Aspera Biomedicines. She has 17+ years of experience working in the life sciences sector as a scientific and medical writer specializing in strategic communications. She is proficient in proposal development and successful planning and delivery of pre- and post-award support. Ms. Mack has a BS in Biology from Virginia Tech, an MS in Scientific Writing from Towson University, and an MS in Biotechnology from University of Maryland Global Campus.
IMG_2650_edited_edited.jpg

Ara Lidstrom

Operations Manager
Ara Lidstrom is the Operations Manager for Aspera Biomedicines. 
 

James J. La Clair

Director, CMC
Dr. James J. La Clair is trained as a synthetic organic chemist. He as been working on the development of Rebecsinib (17S-FD-895) since its discovery.  He brings strong synthetic guidance as well as pharmacological experience to assist the drug development efforts at Aspera Biomedicines.
ASPE_JLACLAIR.jpg
Screen Shot 2022-07-28 at 10.11.43 PM.png

Curtis L. Scribner

Regulatory Affairs
Curtis Scribner, MD, is a board certified internal medicine specialist providing Regulatory Affairs expertise at Aspera Biomedicines. He has very wide experience in drug development as a clinical investigator, regulatory reviewer, and strategic product life cycle consultant. Dr. Scribner spent 10 years at the Center for Biologics Evaluation and Research (CBER), FDA, reviewing all phases of clinical development in a wide breadth of areas. He has more than 25 years of experience as a consultant to drugs and biologics companies working on everything from discovery through clinical trials. 
 
Screen Shot 2022-07-28 at 10.11_edited.p

Peggy Wentworth

Director, Pre-Clinical Operations
Dr. Wentworth is the Director of Pre-Clinical Operations at Aspera Biomedicines. She has more than 20+ years’ experience in drug development and global clinical research and has managed numerous complex programs. Dr. Wentworth has comprehensive expertise in development of biologics and small molecule drugs through all stages of development, including development of oncology therapeutics. Dr. Wentworth has a PhD from Emory University in Immunology and Microbiology.
 

Board of Directors

Cat __edited_edited.jpg

Catriona Jamieson

Magda_Marquet_edited_edited.jpg

Magda Marquet

Sheldon Morris 1 (2)_edited.jpg

Sheldon Morris

Scott Dylla_edited.jpg

Scott

Dylla

bottom of page